logo-loader
HealthCannabis
CB2 Insights

Cb2 Insights signs letter of Intent with UK company, Drug Science for research program TWENTY21

CB2 Insights (CSE: CBII-OTCQB: CBIIT) CEO Prad Sekar joined Steve Darling on Skype from London with news the company has been selected as an exclusive research technology platform for the UK’s largest medical cannabis Pilot – Project TWENTY21

Sekar told Proactive about that project and how CB2 will be involved.

 

Quick facts: CB2 Insights

Price: $0.15

Market: CSE
Market Cap: $11.67 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CB2 Insights named herein, including the promotion by the Company of CB2 Insights in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Rockfire Resources' David Price discusses Brigalow Alluvial...

Rockfire Resources PLC's (LON:ROCK) David Price tells Proactive London's Andrew Scott they've been getting a better understanding of an alluvial gold deposit next one of their main assets in Queensland. Calculations made in 1986 on an area known as Brigalow Alluvial Goldfield has suggested...

22 hours, 54 minutes ago

2 min read